Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCUSERT PILO-40 vs EVOXAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Open-angle glaucoma,Ocular hypertension,Angle-closure glaucoma (emergency treatment),Induction of miosis during ophthalmic surgery,Off-label: Diagnostic miosis
Treatment of dry mouth symptoms in patients with Sjögren's syndrome,Off-label: Management of radiation-induced xerostomia
One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.
30 mg orally three times daily.
Terminal elimination half-life is approximately 1-2 hours; clinical effect duration is extended due to the sustained-release delivery system.
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Primarily metabolized by plasma esterases via hydrolysis, with minor hepatic metabolism (CYP450 not significantly involved).
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes N-oxidation and hydroxylation.
Primarily renal (80-90% as unchanged drug and inactive metabolites); biliary/fecal excretion accounts for <5%.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Binding to plasma proteins is negligible (<10%); primarily bound to tissue proteins in the eye.
Approximately 50-60% bound to plasma proteins, primarily albumin.
0.3-0.6 L/kg in systemic circulation; local ocular distribution is extensive but systemic Vd is low.
Volume of distribution is approximately 6 L/kg, indicating extensive distribution into tissues beyond plasma water.
Systemic bioavailability is minimal (<1%) due to local ocular administration and first-pass hydrolysis; virtually 100% of the released dose is available locally in the eye.
Oral bioavailability is approximately 30% due to extensive first-pass metabolism.
No specific adjustment required; pilocarpine is primarily metabolized in the eye and systemic absorption minimal. GFR not relevant.
For GFR <30 m L/min: not recommended due to increased systemic exposure.
No specific adjustment required; pilocarpine undergoes minimal hepatic metabolism. Child-Pugh not applicable.
No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
Not established; safety and efficacy in pediatric patients not determined. Use only if clearly needed.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment; consider potential increased risk of systemic effects due to reduced tear production or conjunctival changes. Monitor for bradycardia, hypotension, or bronchospasm.
No specific dose adjustment; monitor for increased anticholinergic effects due to age-related reduced clearance.
No FDA black box warning.
None.
Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia,May cause transient or permanent miosis leading to reduced vision in low light,Ciliary spasm, headache, and brow ache,Potential for systemic absorption causing bradycardia, hypotension, and bronchospasm,Caution in patients with asthma, bradycardia, or hypotension
Cardiovascular effects: May cause bradycardia, AV block, hypotension; use caution in patients with cardiovascular disease.,Pulmonary effects: Can exacerbate asthma, chronic bronchitis, or COPD due to increased bronchial secretions.,Ophthalmic effects: May impair night vision or cause visual disturbances; caution when driving at night.,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Caution in moderate to severe hepatic disease.,Potential for sweating and dehydration: Monitor fluid intake.,Drug interactions: Concomitant use with beta-blockers or other cholinergic agents may increase risk of bradycardia.
Hypersensitivity to pilocarpine or any component,Patients with acute inflammatory disease of the eye (e.g., iritis, uveitis),Uncontrolled asthma or severe bradycardia (systemic effects)
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis,Hypersensitivity to cevimeline or any component,Concurrent use with certain anticholinergics (e.g., atropine) due to antagonistic effects
No significant food interactions known. Maintain adequate fluid intake. Avoid alcohol, which may increase risk of side effects like dizziness or blurred vision.
No significant food interactions; may be taken with or without food. However, high-fat meals may delay absorption but not overall effect.
Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and third trimesters, use may cause fetal bradycardia and hypotension. The benefit must justify the potential risk.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variations at doses 2-4 times the maximum recommended human dose. First trimester: Potential risk, use only if benefit justifies risk. Second trimester: Limited data, avoid unless necessary. Third trimester: No specific fetal risks identified, but monitor for maternal cholinergic effects.
Pilocarpine is excreted into breast milk. The M/P ratio is not established. Due to potential for systemic absorption in the infant, use while breastfeeding is not recommended. Monitor infant for cholinergic effects.
Unknown if excreted in human breast milk. M/P ratio not available. Caution advised due to potential for cholinergic side effects in nursing infants. Consider discontinuing nursing or drug, taking into account importance of drug to mother.
Pregnancy may alter the pharmacokinetics of pilocarpine due to increased plasma volume and enhanced metabolic clearance. However, specific dose adjustment guidelines are not established. Titrate to the lowest effective dose to control intraocular pressure and monitor for systemic effects.
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter drug absorption and metabolism; however, no established dose adjustments. Start at lowest effective dose (30 mg three times daily) and titrate based on response and tolerability. Monitor for reduced efficacy or increased toxicity due to pregnancy-induced changes.
Ocusert Pilo-40 is a sustained-release ocular insert delivering pilocarpine 40 mcg/hr for 7 days. Instruct patient to insert into conjunctival cul-de-sac at bedtime to minimize initial blurring and brow ache. Monitor for signs of retinal detachment, especially in myopic patients. Contraindicated in acute iritis, shallow anterior chamber, and narrow-angle glaucoma (can worsen angle closure). Use with caution in patients with corneal abrasions or ulcers. Systemic absorption can cause bradycardia, hypotension, and increased GI motility.
EVOXAC (cevimeline) is a cholinergic agonist used primarily for xerostomia in Sjögren's syndrome; a key pearl is to avoid concurrent use with other parasympathomimetics due to additive effects. Monitor for excessive sweating, bradycardia, and bronchospasm, especially in patients with asthma or COPD. Contraindicated in uncontrolled asthma, iritis, and angle-closure glaucoma. Dose reduction may be required in renal impairment.
Wash hands before handling the insert. Do not touch the eye with the insert.,Insert the oval-shaped Ocusert into the lower conjunctival sac at bedtime; it should not be felt after placement.,The insert works for 7 days; replace with a new one weekly. Remove at the end of the week and discard.,Do not wear contact lenses with Ocusert in place. Remove lenses before insertion and wait 15 minutes before reinserting after removal.,Expect temporary blurred vision and brow ache for the first few hours to days; these side effects often decrease with continued use.,If the insert falls out, rinse it with cool tap water and reinsert quickly. If lost or damaged, use a new one.,Report severe eye pain, vision changes, or redness immediately.,Avoid driving or operating machinery until you know how this medication affects your vision.,Keep out of reach of children; do not use after expiration date.
Take exactly as prescribed, usually three times daily with or without food.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause blurred vision or dizziness.,Report excessive sweating, abdominal cramps, slow heart rate, or difficulty breathing to your healthcare provider immediately.,Do not use with other medications that increase saliva or tear production without consulting your doctor.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCUSERT PILO-40 vs EVOXAC, answered by our medical review team.
OCUSERT PILO-40 is a Ophthalmic Cholinergic Agonist that works by Direct-acting muscarinic agonist; mimics acetylcholine at muscarinic receptors in the eye, causing ciliary muscle contraction and pupillary sphincter contraction, leading to miosis and increased aqueous humor outflow.. EVOXAC is a Cholinergic Agonist that works by Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCUSERT PILO-40 and EVOXAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCUSERT PILO-40 is: One OCUSERT Pilo-40 (2.5 mcg/hr pilocarpine) inserted into the conjunctival cul-de-sac every 7 days.. The standard adult dose of EVOXAC is: 30 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCUSERT PILO-40 and EVOXAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCUSERT PILO-40 is classified as Category C. Pilocarpine is a pregnancy category C drug. Animal studies have shown embryotoxic effects. In the first trimester, there is a potential risk of malformations. In the second and thi. EVOXAC is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.